The global New Chemical Entities (NCE) CDMO market size is predicted to grow from US$ 2878 million in 2025 to US$ 5612 million in 2031; it is expected to grow at a CAGR of 11.8% from 2025 to 2031.

New Chemical Entities (NCE) refer to new compounds that have not yet been approved for any therapeutic use during the drug development process. These compounds are usually obtained through the synthesis or discovery of new molecules and have new activities or therapeutic potential. NCE is usually the first step in drug development, and after evaluating its safety and effectiveness in clinical trials, it may be applied for marketing. CDMO (Contract Development and Manufacturing Organization) refers to a company that provides drug development and production services, usually working with pharmaceutical companies to help them develop and manufacture NCE. CDMO can provide a range of services from preliminary compound synthesis, process development, to the production of drugs for clinical trials and commercial production. In short, NCE is a newly developed drug ingredient, and CDMO is a service provider that specializes in helping pharmaceutical companies develop and produce NCE.

United States market for New Chemical Entities (NCE) CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for New Chemical Entities (NCE) CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for New Chemical Entities (NCE) CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key New Chemical Entities (NCE) CDMO players cover KATSURA CHEMICAL CO., LTD, Regis Custom API, Neuland Laboratories Ltd., Aspen API, Sai Life Sciences, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information) newest research report, the ?New Chemical Entities (NCE) CDMO Industry Forecast? looks at past sales and reviews total world New Chemical Entities (NCE) CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected New Chemical Entities (NCE) CDMO sales for 2025 through 2031. With New Chemical Entities (NCE) CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world New Chemical Entities (NCE) CDMO industry.

This Insight Report provides a comprehensive analysis of the global New Chemical Entities (NCE) CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on New Chemical Entities (NCE) CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global New Chemical Entities (NCE) CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for New Chemical Entities (NCE) CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global New Chemical Entities (NCE) CDMO.

This report presents a comprehensive overview, market shares, and growth opportunities of New Chemical Entities (NCE) CDMO market by product type, application, key players and key regions and countries.

Segmentation by Type:

    Peptide NCE
    Oligonucleotide NCE
    Other

Segmentation by Application:

    Tumors
    Cardiovascular Diseases
    Other

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration.

    KATSURA CHEMICAL CO., LTD
    Regis Custom API
    Neuland Laboratories Ltd.
    Aspen API
    Sai Life Sciences
    Fermion
    Dipharma Francis Srl (Dipharma)
    Cohance
    Suven Pharma
    Syngene
    Aarti Pharmalabs Limited (APL)
    Cerbios-Pharma SA
    PharmaBlock Sciences Nanjing Inc